Show Cart

News Channels

12 Feb 2019 Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) Split Dosing Regimen
12 Feb 2019 Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab
12 Feb 2019 FluGen’s M2SR Influenza Vaccine Succeeds in Phase 2 Human Challenge Trial Against a Highly Mismatched Virus
12 Feb 2019 Alpine Immune Sciences Announces First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program ALPN-101
12 Feb 2019 IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Tay-Sachs and Sandhoff Disease
12 Feb 2019 Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer
12 Feb 2019 Precigen Announces Clearance of IND to Initiate Phase 1 Study for First-in-Class PRGN-3005 UltraCAR-T to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients
12 Feb 2019 Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
12 Feb 2019 3SBio and Verseau Establish Global Clinical Development Collaboration for First-in-class Immuno-Oncology Therapies
12 Feb 2019 Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency
12 Feb 2019 Adverum Biotechnologies Announces Presentation of Preclinical Long-Term Safety Data of ADVM-022 at 2019 Angiogenesis, Exudation, and Degeneration Conference
12 Feb 2019 Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100 (MIW815) in Combination with YERVOY (ipilimumab) for the Treatment of Relapsed and Refractory Melanoma
12 Feb 2019 Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 30-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
12 Feb 2019 European Commission Approves Bristol-Myers Squibb’s Sprycel (dasatinib) in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
12 Feb 2019 European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma
12 Feb 2019 FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
12 Feb 2019 AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma
11 Feb 2019 FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
11 Feb 2019 Immunicum AB (publ) Announces First Patient Treated in Phase Ib/II ILIAD Combination Trial
11 Feb 2019 Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare

Currencies

Shopping cart

Cart empty

Latest report

Featured Products

Latest Target Pipeline

Currencies

Shopping cart

Cart empty

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top